BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 26198262)

  • 1. Comparative immunohistochemical expression of β-catenin, EGFR, ErbB2, and p63 in adamantinomatous and papillary craniopharyngiomas.
    Esheba GE; Hassan AA
    J Egypt Natl Canc Inst; 2015 Sep; 27(3):139-45. PubMed ID: 26198262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of aberrant beta-catenin and impaired p63 in craniopharyngiomas.
    Cao J; Lin JP; Yang LX; Chen K; Huang ZS
    Br J Neurosurg; 2010 Jun; 24(3):249-56. PubMed ID: 20128632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical expression of ErbB2 in adamantinomatous craniopharyngiomas: a possible target for immunotherapy.
    Zuhur SS; Tanik C; Erol RS; Musluman AM; Kabukcuoglu F; Altuntas Y
    Turk Neurosurg; 2013; 23(1):55-60. PubMed ID: 23344868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of β-catenin and BRAF alterations in adamantinomatous and papillary craniopharyngiomas: mutation analysis with immunohistochemical correlation in 54 cases.
    Malgulwar PB; Nambirajan A; Pathak P; Faruq M; Suri V; Sarkar C; Jagdevan A; Sharma BS; Sharma MC
    J Neurooncol; 2017 Jul; 133(3):487-495. PubMed ID: 28500561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possible linkage between specific histological structures and aberrant reactivation of the Wnt pathway in adamantinomatous craniopharyngioma.
    Kato K; Nakatani Y; Kanno H; Inayama Y; Ijiri R; Nagahara N; Miyake T; Tanaka M; Ito Y; Aida N; Tachibana K; Sekido K; Tanaka Y
    J Pathol; 2004 Jul; 203(3):814-21. PubMed ID: 15221941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma.
    Coy S; Rashid R; Lin JR; Du Z; Donson AM; Hankinson TC; Foreman NK; Manley PE; Kieran MW; Reardon DA; Sorger PK; Santagata S
    Neuro Oncol; 2018 Jul; 20(8):1101-1112. PubMed ID: 29509940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Craniopharyngiomas of adamantinomatous type harbor beta-catenin gene mutations.
    Sekine S; Shibata T; Kokubu A; Morishita Y; Noguchi M; Nakanishi Y; Sakamoto M; Hirohashi S
    Am J Pathol; 2002 Dec; 161(6):1997-2001. PubMed ID: 12466115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-resolution melting and immunohistochemical analysis efficiently detects mutually exclusive genetic alterations of adamantinomatous and papillary craniopharyngiomas.
    Yoshimoto K; Hatae R; Suzuki SO; Hata N; Kuga D; Akagi Y; Amemiya T; Sangatsuda Y; Mukae N; Mizoguchi M; Iwaki T; Iihara K
    Neuropathology; 2018 Feb; 38(1):3-10. PubMed ID: 28840946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Common mutations of beta-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region.
    Buslei R; Nolde M; Hofmann B; Meissner S; Eyupoglu IY; Siebzehnrübl F; Hahnen E; Kreutzer J; Fahlbusch R
    Acta Neuropathol; 2005 Jun; 109(6):589-97. PubMed ID: 15891929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemistry or Molecular Analysis: Which Method Is Better for Subtyping Craniopharyngioma?
    Fukuhara N; Iwata T; Inoshita N; Yoshimoto K; Kitagawa M; Fukuhara H; Tatsushima K; Yamaguchi-Okada M; Takeshita A; Ito J; Takeuchi Y; Yamada S; Nishioka H
    Endocr Pathol; 2021 Jun; 32(2):262-268. PubMed ID: 32965631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Craniopharyngiomas: A clinicopathological and molecular study of 52 cases - Experience in the Complejo Hospitalario de Toledo and Hospital Universitario 12 de Octubre (Madrid).
    Moreno-Torres B; Campos-Martín Y; Meléndez B; Garcia Martin RM; Vicente A; Rodríguez de Lope Á; Alen JF; Mollejo M; Hernández-Laín A
    Clin Neuropathol; 2021; 40(1):26-35. PubMed ID: 33040839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TREM-1 expression in craniopharyngioma and Rathke's cleft cyst: its possible implication for controversial pathology.
    Liu Y; Wang CH; Li DL; Zhang SC; Peng YP; Peng JX; Song Y; Qi ST; Pan J
    Oncotarget; 2016 Aug; 7(31):50564-50574. PubMed ID: 27409178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Implication of BRAF V600E and CTNNB1 gene mutations in the pathological classification of craniopharyngioma].
    Xu SS; Wang LM; Zhao LH; He ZL; Gong LP; Lu DH; Teng LH
    Zhonghua Bing Li Xue Za Zhi; 2019 Sep; 48(9):682-687. PubMed ID: 31495087
    [No Abstract]   [Full Text] [Related]  

  • 14. Do craniopharyngioma molecular signatures correlate with clinical characteristics?
    Omay SB; Chen YN; Almeida JP; Ruiz-Treviño AS; Boockvar JA; Stieg PE; Greenfield JP; Souweidane MM; Kacker A; Pisapia DJ; Anand VK; Schwartz TH
    J Neurosurg; 2018 May; 128(5):1473-1478. PubMed ID: 28707994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Wnt signalling cascade and the adherens junction complex in craniopharyngioma tumorigenesis.
    Preda V; Larkin SJ; Karavitaki N; Ansorge O; Grossman AB
    Endocr Pathol; 2015 Mar; 26(1):1-8. PubMed ID: 25355426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of neuroendocrine dysfunction in patients with adamantinomatous and papillary craniopharyngiomas.
    Feng Y; Ni M; Wang YG; Zhong LY
    Exp Ther Med; 2019 Jan; 17(1):51-56. PubMed ID: 30651764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathology and pathogenesis of craniopharyngiomas.
    Larkin SJ; Ansorge O
    Pituitary; 2013 Mar; 16(1):9-17. PubMed ID: 22886701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of the Canonical Wnt Pathway Activation on the Pathogenesis and Prognosis of Adamantinomatous Craniopharyngiomas.
    Jucá CEB; Colli LM; Martins CS; Campanini ML; Paixão B; Jucá RV; Saggioro FP; de Oliveira RS; Moreira AC; Machado HR; Neder L; Antonini SR; de Castro M
    Horm Metab Res; 2018 Jul; 50(7):575-581. PubMed ID: 29625497
    [No Abstract]   [Full Text] [Related]  

  • 19. Expression of enamel proteins and LEF1 in adamantinomatous craniopharyngioma: evidence for its odontogenic epithelial differentiation.
    Sekine S; Takata T; Shibata T; Mori M; Morishita Y; Noguchi M; Uchida T; Kanai Y; Hirohashi S
    Histopathology; 2004 Dec; 45(6):573-9. PubMed ID: 15569047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subtype-dependent difference of glucose transporter 1 and hexokinase II expression in craniopharyngioma: an immunohistochemical study.
    Mukada N; Tosaka M; Matsumura N; Yamaguchi R; Aihara M; Isoda K; Higuchi T; Tsushima Y; Yokoo H; Yoshimoto Y
    Sci Rep; 2021 Jan; 11(1):126. PubMed ID: 33420213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.